1. Kaps L, Limeres MJ, Schneider P, Svensson M, Zeyn Y, Fraude S, et al. Liver cell type-specific targeting by nanoformulations for therapeutic applications. Int J Mol Sci. 2023;24(14):11869. [
DOI:10.3390/ijms241411869] [
PMID] [
]
2. Wang X, Yang L, Wang Y-C, Xu Z-R, Feng Y, Zhang J, et al. Comparative analysis of cell lineage differentiation during hepatogenesis in humans and mice at the single-cell transcriptome level. Cell Res. 2020;30(12):1109-26. [
DOI:10.1038/s41422-020-0378-6] [
PMID] [
]
3. Lemaigre F, Zaret KS. Liver development update: new embryo models, cell lineage control, and morphogenesis. Curr Opin Genet Dev. 2004;14(5):582-90. [
DOI:10.1016/j.gde.2004.08.004] [
PMID]
4. Tremblay KD, Zaret KS. Distinct populations of endoderm cells converge to generate the embryonic liver bud and ventral foregut tissues. Dev Biol. 2005;280(1):87-99. [
DOI:10.1016/j.ydbio.2005.01.003] [
PMID]
5. Xu J, Hao S, Shi Q, Deng Q, Jiang Y, Guo P, et al. Transcriptomic profile of the mouse postnatal liver development by single-nucleus RNA sequencing. Front. Cell Dev.Biol. 2022;10:833392. [
DOI:10.3389/fcell.2022.833392] [
PMID] [
]
6. Ober EA, Lemaigre FP. Development of the liver: Insights into organ and tissue morphogenesis. J Hepatol. 2018;68(5):1049-62. [
DOI:10.1016/j.jhep.2018.01.005] [
PMID]
7. Akinosoglou K, Schinas G, Gogos C. Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir. Viruses. 2022;14(11):2540. [
DOI:10.3390/v14112540] [
PMID] [
]
8. Amani, B., & Amani, B. (2023). Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: a rapid review and meta‐analysis. J. Med Virol, 95(2), e28441. [
DOI:10.1002/jmv.28441] [
PMID] [
]
9. Hashemian SMR, Sheida A, Taghizadieh M, Memar MY, Hamblin MR, Baghi HB, et al. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Biomed Pharmacother. 2023;162:114367. [
DOI:10.1016/j.biopha.2023.114367] [
PMID] [
]
10. McCarthy MW. McCarthy MW. Optimizing the use of Paxlovid in clinical practice. Drugs Today (Barc). 2022;58(11):539-546. [
DOI:10.1358/dot.2022.58.11.3461265] [
PMID]
11. Catlin N, Bowman C, Campion S, Cheung J, Nowland W, Sathish J, et al. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models. Reprod Toxicol. 2022;108:56-61. [
DOI:10.1016/j.reprotox.2022.01.006] [
PMID] [
]
12. Bege M, Borbás A. The Design, Synthesis and Mechanism of Action of Paxlovid, a Protease Inhibitor Drug Combination for the Treatment of COVID-19. Pharm. 2024;16(2):217. [
DOI:10.3390/pharmaceutics16020217] [
PMID] [
]
13. Lamb YN. Nirmatrelvir plus ritonavir: first approval. Drugs. 2022;82(5):585-91. [
DOI:10.1007/s40265-022-01692-5] [
PMID] [
]
14. Imam MS, Batubara AS, Gamal M, Abdelazim AH, Almrasy AA, Ramzy S. Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations. Sci Rep. 2023;13(1):137. [
DOI:10.1038/s41598-022-26944-y] [
PMID] [
]
15. Pasley MV, Martinez M, Hermes A, d'Amico R, Nilius A. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review. AIDS Rev. 2013;15(1):38-48. [
GOOGLE SCHOLAR]
16. Vangelotti A, Júnior EA, Simões M, Amed A, Nakamura M, Júnior LK. Chronic action of lamivudine and ritonavir on maternal and fetal liver and kidney of albino pregnant rats (Rattus norvegicus albinus, Rodentia, Mammalia): morphological and biochemical aspects. Clin Exp Obstet Gynecol. 2015;42(4):523-8. [
DOI:10.12891/ceog1885.2015] [
PMID]